

**BIOFERR 90- dual-iron tablet, film coated**  
**Biocomp Pharma, Inc.**

*Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click [here](#).*

-----  
**BioFerr™ 90**

**Warning:** Accidental overdose of **iron-containing** products is a leading cause of fatal poisoning in children under 6. KEEP THIS PRODUCT OUT OF THE REACH OF CHILDREN. In case of accidental overdose, call a doctor or poison control center immediately.

**DESCRIPTION:**

Each green film-coated tablet for oral administration contains:

Iron (Carbonyl iron, ferrous gluconate)	90	mg
Folic Acid	1	mg
Vitamin B <sub>12</sub> (Cyanocobalamin)	12	mcg
Vitamin C (Ascorbic acid)	119	mg
Docusate sodium	50	mg

**Inactive Ingredients:**

Povidone, croscarmellose sodium, acrylic resin, color added, magnesium stearate, FD&C Yellow No. 5, magnesium silicate, FD&C Blue No. 1, polyethylene glycol, vitamin A palmitate, ethyl vanillin.

**CLINICAL PHARMACOLOGY:**

Oral iron is absorbed most efficiently when administered between meals. Iron is critical for normal hemoglobin synthesis to maintain oxygen transport for energy production and proper function of cells. Adequate amounts of iron are necessary for effective erythropoiesis. Iron also serves as a cofactor of several essential enzymes, including cytochromes, which are involved in electron transport. Folic acid is required for nucleoprotein synthesis and the maintenance of normal erythropoiesis. Folic acid is the precursor of tetrahydrofolic acid, which is involved as a cofactor for transformylation reactions in the biosynthesis of purines and thymidylates of nucleic acids. Deficiency of folic acid may account for the defective deoxyribonucleic acid (DNA) synthesis that leads to megaloblast formation and megaloblastic macrocytic anemias. Vitamin B<sub>12</sub> is essential to growth, cell reproduction, hematopoiesis, nucleic acid, and myelin synthesis. Deficiency may result in megaloblastic anemia or pernicious anemia.

**INDICATIONS AND USAGE:**

BioFerr™ 90 is indicated for the treatment of all anemias that are responsive to oral iron therapy. These include: hypochromic anemia associated with pregnancy, chronic and/or acute blood loss, metabolic disease, post-surgical convalescence, and dietary needs.

**CONTRAINDICATIONS:**

Hypersensitivity to any of the ingredients. Hemolytic anemia, hemochromatosis, and hemosiderosis are contraindications to iron therapy.

**WARNING:**

Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemia where vitamin B<sub>12</sub> is deficient.

**PRECAUTIONS:****General:**

Take 2 hours after meals. Do not exceed recommended dose. Discontinue use if symptoms of intolerance appear. The type of anemia and underlying cause or causes should be determined before starting therapy with BioFerr™ 90 tablets. Ensure Hgb, Hct, and reticulocyte count are determined before starting therapy to determine if it needs to be continued without change or if a dose change is indicated. This product contains FD&C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.

**Folic Acid:**

Folic acid in doses above 0.1 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations remain progressive. Pernicious anemia should be excluded before using these products since folic acid may mask the symptoms of pernicious anemia.

**Pediatric Use:**

Safety and effectiveness in pediatric patients have not been established.

**Geriatric Use:**

Dosing for elderly patients should be administered with caution. Due to the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy, dosing should start at the lower end of the dosing range.

**ADVERSE REACTIONS:**

Adverse reactions with iron therapy may include GI irritation, constipation, diarrhea, nausea, vomiting, and dark stools. Adverse reactions with iron therapy are usually transient. Allergic sensitization has been reported following both oral and parenteral administration of folic acid.

**DRUG INTERACTIONS:**

Prescriber should be aware of a number of iron/drug interactions, including antacids, tetracyclines, or fluoroquinolones.

**OVERDOSAGE:**

Symptoms: abdominal pain, metabolic acidosis, anuria, CNS damage, coma, convulsions, death, dehydration, diffuse vascular congestion, hepatic cirrhosis, hypotension, hypothermia, lethargy, nausea, vomiting, diarrhea, tarry stools, melena, hematemesis, tachycardia, hyperglycemia, drowsiness, pallor, cyanosis, lassitude, seizures, and shock

**DOSAGE AND ADMINISTRATION**

One tablet daily or as directed by a physician.

Do not chew tablet.

**STORAGE:**

Store at 20°C to 25°C (68°F to 77°F). Excursions permitted between 15°C and 30°C (between 59°F and 86°F). (See USP Controlled Room Temperature.)

**NOTICE:**

Contact with moisture can discolor or erode the tablet.

**HOW SUPPLIED:**

BioFerr™ 90 (NDC 44523-732-90) is a green, modified rectangle shaped, film-coated tablet, debossed with “F7” on one side and blank on the other, and packaged in bottles of 90.

**To report** a serious adverse event or obtain product information, call (210) 696-8400.

L73290 C01 Rev 004140

BioComp Pharma® Inc., San Antonio, TX 78230 1355

BioFerr™ 90  
90 mg Dual-Iron Tablets  
NDC 44523-732-90

77469

progressive. Pernicious anemia should be excluded before using these products since folic acid may mask the symptoms of pernicious anemia.

These products are contraindicated in patients with known hypersensitivity to the active ingredients. BioFerr<sup>®</sup> 90 is a green, modified rectangle shaped, film-coated tablet. Should be administered with caution. Due to the greater frequency of decreased folic acid, or cardiac function, and of concomitant disease or other drug therapy, the usual starting dose of the lower end of the dosing range should be used.

**ADVERSE REACTIONS:** Adverse reactions with iron therapy may include GI irritation, constipation, diarrhea, nausea, vomiting, and dark stools. Adverse reactions with iron therapy are usually transient. Allergic reactions to the inactive ingredients may occur both oral and parenteral administration of folic acid.

**DRUG INTERACTIONS:** Prescriber should be aware of a number of iron-folic acid interactions, including antacids, antidiarrheals, and laxatives.

**CONTRAINDICATIONS:** Systemic iron therapy, neurotoxic reactions, CNS damage, coma, convulsions, death, dehydration, diffuse vascular congestion, hepatic cirrhosis, hypotension, hypothermia, kidney, nausea, vomiting, diarrhea, tarry stools, tachycardia, angioedema, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, hypophosphatemia, hypotriphosphatemia, leukopenia, sepsis, shock, syncope, and stroke.

**DOSE AND ADMINISTRATION:** One tablet daily or as directed by a physician. Do not chew tablet.

**STORAGE:** Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). (See USP Controlled Room Temperature).

**NOTICE:** Contact with moisture can discolor or erode the label.

**HOW SUPPLIED:** BioFerr<sup>®</sup> 90 (NDC 44523-732-90) is a green, modified rectangle shaped, film-coated tablet, debossed with "90" on one side and blank on the other, and packaged in bottles of 90.

To report a serious adverse event or obtain product information, call (210) 686-9400.

L73290 001 Rev 004140

**BioComp**  
Pharm, Inc.  
BioComp Pharm, Inc., San Antonio, TX 78290-1356

Read prescribing information for **DOSE AND ADMINISTRATION**.  
**WARNING:** Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. **KEEP THIS PRODUCT OUT OF THE REACH OF CHILDREN.** In case of accidental overdose, call a doctor or poison control center immediately.

NDC 44523-732-90

Rx Only

**BioFerr<sup>®</sup> 90****90 mg Dual-Iron Tablets**

N 44523-732-90 2

90 Coated Tablets BioComp Pharm.

**DESCRIPTION:** Each green film-coated tablet for oral administration contains: Iron (Carbonyl Iron, Ferrous Gluconate) 90 mg, Folic Acid 1 mg, Ascorbic Acid 138 mg, Cyanocobalamin 16.8 mcg, and Docusate Sodium 55 mg.

**CLINICAL PHARMACOLOGY:** Oral iron is absorbed most efficiently when administered between meals. Iron is critical for normal hemoglobin synthesis to maintain oxygen transport for energy production and proper function of all cellular enzymes. Iron deficiency may be a risk for children. Iron also serves as a cofactor of several essential enzymes, including cytochromes, which are involved in electron transport. Folic acid is required for nucleoprotein synthesis and the maintenance of normal hematopoiesis. Deficiency may result in megaloblastic anemia or pernicious anemia. Vitamin B<sub>12</sub> (cyanocobalamin) is essential for the maturation of red blood cells. These include: hypochromic anemia associated with pregnancy, chronic and/or acute blood loss, metabolic disease, post-surgical consequences, and dietary needs. Cyanocobalamin deficiency may result in all of the hematologic, hematopoietic, neurochemical, and hematodynamic contributions to iron therapy.

**WARNINGS:** Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias.

**PRECAUTIONS:** General: Use 2 hours after meals. Do not use if expired. Do not use if you experience any symptoms of intolerance or signs of hypoxia. The type of anemia and underlying cause or causes should be determined before starting therapy with BioFerr<sup>®</sup> 90 tablets. Ensure high Hct and reticulocyte count are determined before starting therapy and periodic re-evaluation of therapy and patient response. Discontinue therapy to determine if it needs to be continued without change or if a dose change is indicated. This product contains Folic Acid Yellow No. 5 (excipients) which may cause allergic-type reactions including anaphylactic symptoms or other allergic reactions in persons. Although the overall incidence of Folic Acid Yellow No. 5 (excipients) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.

Folic Acid: Folic acid is known above 0.1 mg daily may cause an increase in the risk that hematologic manifestations occur which neurologic manifestations remain.

**DESCRIPTION:** Each green film-coated tablet for oral administration contains:

Iron (Carbonyl Iron, Ferrous Gluconate) 90 mg  
Folic Acid 1 mg  
Ascorbic Acid 138 mg  
Cyanocobalamin 16.8 mcg  
Docusate Sodium 55 mg

**CLINICAL PHARMACOLOGY:** Oral iron is absorbed most efficiently when administered between meals. Iron is critical for normal hemoglobin synthesis to maintain oxygen transport for energy production and proper function of all cellular enzymes. Iron deficiency may be a risk for children. Iron also serves as a cofactor of several essential enzymes, including cytochromes, which are involved in electron transport. Folic acid is required for nucleoprotein synthesis and the maintenance of normal hematopoiesis. Deficiency may result in megaloblastic anemia or pernicious anemia. Vitamin B<sub>12</sub> (cyanocobalamin) is essential for the maturation of red blood cells. These include: hypochromic anemia associated with pregnancy, chronic and/or acute blood loss, metabolic disease, post-surgical consequences, and dietary needs. Cyanocobalamin deficiency may result in all of the hematologic, hematopoietic, neurochemical, and hematodynamic contributions to iron therapy.

**WARNINGS:** Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias.

**PRECAUTIONS:** General: Use 2 hours after meals. Do not use if expired. Do not use if you experience any symptoms of intolerance or signs of hypoxia. The type of anemia and underlying cause or causes should be determined before starting therapy with BioFerr<sup>®</sup> 90 tablets. Ensure high Hct and reticulocyte count are determined before starting therapy and periodic re-evaluation of therapy and patient response. Discontinue therapy to determine if it needs to be continued without change or if a dose change is indicated. This product contains Folic Acid Yellow No. 5 (excipients) which may cause allergic-type reactions including anaphylactic symptoms or other allergic reactions in persons. Although the overall incidence of Folic Acid Yellow No. 5 (excipients) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.

Folic Acid: Folic acid is known above 0.1 mg daily may cause an increase in the risk that hematologic manifestations occur which neurologic manifestations remain.

**BioFerr<sup>®</sup> 90****90 mg Dual-Iron Tablets**

N 44523-732-90 2

90 Coated Tablets BioComp Pharm.

Read prescribing information for **DOSE AND ADMINISTRATION**.  
**WARNING:** Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. **KEEP THIS PRODUCT OUT OF THE REACH OF CHILDREN.** In case of accidental overdose, call a doctor or poison control center immediately.

**DESCRIPTION:** Each green film-coated tablet for oral administration contains: Iron (Carbonyl Iron, Ferrous Gluconate) 90 mg, Folic Acid 1 mg, Ascorbic Acid 138 mg, Cyanocobalamin 16.8 mcg, and Docusate Sodium 55 mg.

**CLINICAL PHARMACOLOGY:** Oral iron is absorbed most efficiently when administered between meals. Iron is critical for normal hemoglobin synthesis to maintain oxygen transport for energy production and proper function of all cellular enzymes. Iron deficiency may be a risk for children. Iron also serves as a cofactor of several essential enzymes, including cytochromes, which are involved in electron transport. Folic acid is required for nucleoprotein synthesis and the maintenance of normal hematopoiesis. Deficiency may result in megaloblastic anemia or pernicious anemia. Vitamin B<sub>12</sub> (cyanocobalamin) is essential for the maturation of red blood cells. These include: hypochromic anemia associated with pregnancy, chronic and/or acute blood loss, metabolic disease, post-surgical consequences, and dietary needs. Cyanocobalamin deficiency may result in all of the hematologic, hematopoietic, neurochemical, and hematodynamic contributions to iron therapy.

**WARNINGS:** Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias.

**PRECAUTIONS:** General: Use 2 hours after meals. Do not use if expired. Do not use if you experience any symptoms of intolerance or signs of hypoxia. The type of anemia and underlying cause or causes should be determined before starting therapy with BioFerr<sup>®</sup> 90 tablets. Ensure high Hct and reticulocyte count are determined before starting therapy and periodic re-evaluation of therapy and patient response. Discontinue therapy to determine if it needs to be continued without change or if a dose change is indicated. This product contains Folic Acid Yellow No. 5 (excipients) which may cause allergic-type reactions including anaphylactic symptoms or other allergic reactions in persons. Although the overall incidence of Folic Acid Yellow No. 5 (excipients) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.

Folic Acid: Folic acid is known above 0.1 mg daily may cause an increase in the risk that hematologic manifestations occur which neurologic manifestations remain.

## BIOFERR 90

dual-iron tablet, film coated

### Product Information

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:44523-732
<b>Route of Administration</b>	ORAL		

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
<b>ASCORBIC ACID</b> (UNII: PQ6CK8PD0R) (ASCORBIC ACID - UNII:PQ6CK8PD0R)	ASCORBIC ACID	138 mg
<b>IRON PENTACARBONYL</b> (UNII: 6WQ62TAQ6Z) (FERROUS CATION - UNII:GW89581OWR)	FERROUS CATION	88.5 mg
<b>DOCUSATE SODIUM</b> (UNII: F05Q2T2JA0) (DOCUSATE - UNII:M7P27195AG)	DOCUSATE SODIUM	55 mg
<b>FERROUS GLUCONATE</b> (UNII: U1B11423Z) (FERROUS CATION - UNII:GW89581OWR)	FERROUS CATION	13.2 mg
<b>FOLIC ACID</b> (UNII: 935E97BOY8) (FOLIC ACID - UNII:935E97BOY8)	FOLIC ACID	1.4 mg
<b>CYANO COBALAMIN</b> (UNII: P6YC3EG204) (CYANOCOBALAMIN - UNII:P6YC3EG204)	CYANOCOBALAMIN	16.8 ug

### Inactive Ingredients

Ingredient Name	Strength
<b>POVIDONES</b> (UNII: FZ989GH94E)	
<b>CROSCARMELLOSE SODIUM</b> (UNII: M28OL1HH48)	

<b>DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER</b> (UNII: 905HNO1SIH)	
<b>TITANIUM DIOXIDE</b> (UNII: 15FIX9V2JP)	
<b>MAGNESIUM STEARATE</b> (UNII: 70097M6I30)	
<b>FD&amp;C YELLOW NO. 5</b> (UNII: I753WB2F1M)	
<b>MAGNESIUM SILICATE</b> (UNII: 9B9691B2N9)	
<b>FD&amp;C BLUE NO. 1</b> (UNII: HBR47K3TBD)	
<b>POLYETHYLENE GLYCOLS</b> (UNII: 3WJQ0SDW1A)	
<b>VITAMIN A PALMITATE</b> (UNII: 1D1K0N0VVC)	
<b>ETHYL VANILLIN</b> (UNII: YC9ST449YJ)	

### Product Characteristics

<b>Color</b>	GREEN	<b>Score</b>	no score
<b>Shape</b>	RECTANGLE (modified rectangle)	<b>Size</b>	9 mm
<b>Flavor</b>		<b>Imprint Code</b>	F7
<b>Contains</b>			

### Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:44523-732-90	90 in 1 BOTTLE		

### Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
Unapproved drug other		07/01/2014	

**Labeler** - Biocomp Pharma, Inc. (829249718)

**Registrant** - Mission Pharmacal Company (927726893)

### Establishment

Name	Address	ID/FEI	Business Operations
Mission Pharmacal Company		927726893	MANUFACTURE(44523-732)

Revised: 6/2014

Biocomp Pharma, Inc.